A metabolic approach to hepatitis C;Vers une approche métabolique de l'hépatite C

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C1, 2007, Pages 639-640

  Fartoux, Lætitia ^a   Serfaty, Lawrence ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CARDIOVASCULAR RISK; DISEASE COURSE; EDITORIAL; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULINEMIA; LIVER DISEASE; LIVER FIBROSIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; PREVALENCE; VIRUS INFECTION; VIRUS LOAD;

EID: 34948824849     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)91910-7     Document Type: Editorial

References (14)

1. Moucari R, Marcellin P, Asselah T. Stéatose au cours de l'hépatite chronique C : rôle de l'insulino-résistance et des facteurs viraux. Gastroenterol Clin Biol 2007;31:643-54.
2. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin Resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54:1003-8.
3. Lecube A, Hernandez C, Genesca J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection. Diabetes Care 2006;29:1140-49.
4. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Insulin resistance impairs sustained response rate to peginterferon plus ribavirin inchronic hepatitis C patients. Gastroenterology 2005;128:636-41.
5. Cattaneo D, Pericio N, Remuzzi G. Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: are there practical implications? J Hepatol 2006;44:837-8.
6. Momiyama Y, Ohmori R, Kato R, Taniguchi H, Nakamura H, Ohsuzu F. Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease. Atherosclerosis 2005;181:211-3.
7. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoolic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007;46:1126-32.
8. Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005;90: 2240-3.
9. Hickmann JJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
10. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
11. Poynard T, Ratziu V, McHutchinson J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
12. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7.
13. Sanyal AJ, Chand N, Comar K, Mirshahi. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and non-alcoholic fatty liver disease. (abstract) Hepatology 2004;40:179A.
14. Simo R, Lecube A, Genesca J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006;29:2462-6.